Tagged with P

MEA As global pharmaceutical strategies continue to shift, Ali Sleiman reflects on how Genesys Pharmaceuticals is being built as a disciplined execution platform for the Middle East and Africa. The interview explores how distributor-led models, portfolio selectivity, and strong infrastructure shape access to innovation, including in rare diseases, against an increasingly…

Taiwan Professor Chi-Huey Wong serves as President of the Institute for Biotechnology and Medicine Industry (IBMI) in Taiwan, bringing decades of distinguished experience from top-tier US research institutions including MIT, Scripps Research and his tenure as President of Academia Sinica. With a unique vantage point spanning both American and Taiwanese scientific…

Taiwan Built around an engineering mindset and a clear view of where a smaller biotech can compete, Pharmosa is pursuing a differentiated path in pulmonary hypertension and related rare diseases through drug-device combination therapies. In this discussion, Pei Kan outlines how scientific focus, selective partnerships, disciplined capital allocation, and early investment…

LatAm Dirk van Niekerk, President and CEO of Boehringer Ingelheim South America, identifies Latin America as a pivotal growth engine. Focusing on cardio, renal, metabolic and oncology pillars, the firm is navigating patent gaps through innovative stroke care networks and advanced data analytics, while championing regional talent and sustainable healthcare delivery.…

Taiwan Pei-Jiun Chen, CEO and President of Mycenax, outlines the company’s evolution into a focused, end-to-end biologics CDMO with deep roots in development excellence and GMP manufacturing. She highlights Japan as Mycenax’s core market, expansion into Europe, disciplined capacity growth, automation-driven productivity, and a niche, customer-centric model supporting complex biologics and…

Hong Kong Nearly two years on from our last conversation with Henry Yau, Hong Kong’s clinical trials narrative has shifted from institutional intent to operational execution. The managing director of the HKU Clinical Trials Centre reflects on how regulatory reform, ecosystem coordination, and on-the-ground capability are now aligning, repositioning clinical research as…

USA At a moment when rare disease policy, diagnostics, and patient-driven research are converging, Danielle Carnival sets out a clear vision for the role of the Undiagnosed Diseases Network Foundation. Drawing on her experience across neuroscience, federal health policy, and patient-led organisations, she explains how UDNF operates upstream of diagnosis, addressing…

France Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl Eskjær, Denmark’s Ambassador to France, reflects on how complementary strengths in research, digital health and public-private collaboration are shaping a…

USA Genome editing is moving from proof of concept to clinical reality, but questions around scale, cost, and responsibility now define its future. In this interview, Brad Ringeisen outlines how the Innovative Genomics Institute is shaping CRISPR as a platform for real-world impact, bridging philanthropy, academia, and industry while navigating regulation,…

USA North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the combination of large-scale capacity, experienced talent, and a tightly integrated site network is shaping a long-term manufacturing platform designed for…

Global ISPOR’s Rob Abbott traces AI’s evolution in healthcare from early expert systems to today’s machine learning and large language models, arguing that AI is now central to health economics and outcomes research (HEOR) and healthcare decision-making. Abbott highlights concrete use cases in genomics, evidence synthesis, and medical imaging, while stressing…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include WuXi XDC’s acquisition of TOT Biopharm to expand ADC CDMO capabilities, Sino Biopharma’s entry into RNAi therapeutics with the acquisition of Hygieia, and RemeGen’s US$ 5.6 billion licensing deal with AbbVie. IPO filings by Exegenesis, Immvira, and Genhouse Bio,…